Novo-Nordisk A/S NVO
US equityMarket cap rank #103
$40.31 +$0.01 (+0.02%)
Market closed · Nov 6, 8:10 pm ET · Last extended-hours $40.34 +0.08%
Open$39.76
Prev close$40.30
Day range$39.53 – $40.55
Volume9.24M
Market cap$179.98B
P/E (TTM)10.5
Dividend yield4.39%
NVO Stock News
Headlines matching Novo-Nordisk A/S or the NVO ticker, most recent first.
- Eli Lilly and Co (LLY.US) and Novo-Nordisk A/S (NVO.US) win GLP-1 antitrust lawsuit as U.S. court dismisses allegations by rival pharmacy Mixed
- Novo-Nordisk A/S (NVO.US) Q2 earnings beat expectations and full-year guidance was raised, yet underlying concerns persist! Weak sales of oral Wegovy cast a shadow over its path back to growth. Positive
- BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Maintains Target Price $47
- Defiance Daily Target 2X Long NVO ETF | NPORT-P: Others
- BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Maintains Target Price $47
- TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Maintains Target Price $42
- Morgan Stanley Downgrades Novo-Nordisk A/S(NVO.US) to Sell Rating, Maintains Target Price $40 Negative
- Novo Resources Corp: Statement of CDIs on issue - NVO
- BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Raises Target Price to $47 Positive
- Analysts' Opinions Are Mixed on These Healthcare Stocks: BrightSpring Health Services, Inc. (BTSG), AbbVie (ABBV) and Novo Nordisk (NVO)
- Novo-Nordisk A/S (NVO.US) has submitted a marketing application in China for Wegovy tablets for long-term weight management.
- Defiance Daily Target 2X Long NVO ETF | 497K: Others
- Goldman Sachs Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Raises Target Price to $47 Positive
- BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Maintains Target Price $45
- Goldman Sachs Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Cuts Target Price to $40 Negative
No comments yet — be the first to weigh in on NVO.